What Blastomat Treats: Main Uses and Benefits

Blastomat is commonly used across conditions associated with high-grade malignant gliomas, such as Glioblastoma multiforme (GBM) and Anaplastic Astrocytoma. The medication is considered relevant for conditions that are newly diagnosed, often in contexts involving heightened systemic burden requiring comprehensive treatment. This provides assistance that supports general well-being during symptomatic phases and may assist with maintaining functional stability when symptoms interfere with routine activities.

It is also generally applied in clinical settings that involve recurrent or progressive malignant glioma, where symptoms may intensify temporarily. The use of this medication helps support the patient during difficult episodes by easing the overall symptom load and maintaining a sense of stability when symptoms are more noticeable. This is relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden, such as during multi-modal therapy.

---

Quick Fact: Support for Symptom Manifestations

Feature	Description
Primary Target	Conditions associated with high-grade malignant gliomas
Key Use Scenario	Newly diagnosed and recurrent disease manifestations
Symptomatic Benefit	Helps manage symptom clusters that may become intense or disruptive
Clinical Context	Applied in clinical settings that involve acute or unstable symptom patterns

Eligibility and Contraindications

Blastomat (temozolomide) is officially indicated for the treatment of newly diagnosed glioblastoma multiforme in adults, given first with radiotherapy and then alone. It is also approved for recurrent or progressive malignant glioma (such as glioblastoma or anaplastic astrocytoma) in adults and in children three years of age and older.

Use of the medicine is contraindicated (prohibited) for patients with a known hypersensitivity to the active substance, any of its ingredients, or to the related anticancer medicine dacarbazine. It is also strictly prohibited in patients with severe myelosuppression (significantly low blood cell counts) prior to the start of treatment, requiring specific hematological levels to be met.

Restrictions and Special Considerations

Population Category	Eligibility Status (Official)
Pregnancy	Contraindicated unless the potential benefit outweighs the risk of fetal harm.
Lactation	Not Recommended (nursing mothers should be advised to discontinue breastfeeding).
Severe Renal/Hepatic Impairment	Caution should be exercised; no established dose for severe impairment.
Children under 3 years	Use not established for recurrent malignant glioma.

Treatment must be prescribed by a physician experienced in the oncological treatment of brain tumors, and dose adjustments are mandatory if blood cell counts fall below specified thresholds during therapy.

Interactions with other medicines and products

Official regulatory documentation for Blastomat (Temozolomide) establishes specific interaction patterns regarding pharmacokinetics, pharmacodynamics, and administration timing.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class	Officially Documented Effect	Classification
Valproic Acid (VPA)	Decreases Temozolomide oral clearance and increases systemic exposure.	Pharmacokinetic
Myelosuppressive Agents	Increases the official potential for additive bone marrow toxicity (myelosuppression).	Pharmacodynamic
Live Vaccines	Co-administration is generally not recommended due to the risk of systemic infection.	Pharmacodynamic

Administration and Timing Constraints

The regulatory profile includes a mandatory administration-timing constraint related to food intake. Administration of the oral capsule with food is officially documented to result in a reduction in the rate and extent of absorption, specifically decreasing the peak plasma concentration (Cmax) by approximately 33%. To mitigate this effect, the capsule must be administered on an empty stomach.

Population-Specific Notes

Official documents note that patients 70 years of age or older have a heightened susceptibility to severe myelosuppression. This increases the clinical relevance of pharmacodynamic interactions with other myelosuppressive medicines in this specific age group.

Blastomat (Temozolomide) exerts its physiological effect through a precise, cascade-driven cytotoxic mechanism initiated by chemical modification of cellular DNA. The small size and lipophilicity of the molecule allow it to readily cross the Blood-Brain Barrier (BBB), ensuring its activity can be delivered to cell populations within the Central Nervous System (CNS).

The drug functions as a prodrug that spontaneously converts in the body into a methylating species. This species introduces a covalent modification, primarily at the O^6 position of the Guanine base in DNA. The resultant O^6 -MeG lesion is recognized by the DNA Mismatch Repair (MMR) System, which attempts futile repair cycles that generate lethal DNA strand breaks.

The accumulation of this irreparable damage forces cell cycle arrest and activates the apoptosis pathway, leading to a reduction in the population of affected proliferating cells. The mechanism is constrained by the MGMT enzyme; high levels of this enzyme neutralize the DNA lesion, counteracting the cytotoxic mechanism and determining the limit of the drug's action.

How to Use Blastomat: Administration Guidelines

This section outlines the administration protocols for Blastomat as established for clinical use.

Administration Scope

The usage of Blastomat involves both oral and intravenous (IV) infusion routes, depending on the specific regimen outlined by the prescriber.

Feature	Oral Administration	Intravenous Infusion
Dose (Standard)	100 mg once daily	5 mg/kg body weight
Frequency	Once every 24 hours	Day 1 of a 21-day cycle
Duration	Continued until disease progression or unacceptable toxicity	Typically up to 6 cycles

Preparation and Procedural Instructions

Oral Administration:

• Tablets must be swallowed whole. Do not crush, chew, or divide the tablets.
• May be taken with or without food.
• If a dose is missed, take the next scheduled dose at the regular time. Do not double the dose.

Intravenous Administration:

• The solution must be diluted in 250 mL of 0.9% Sodium Chloride Injection prior to administration.
• The final concentration must not exceed 2 mg/mL after dilution.
• The infusion must be administered slowly, over a minimum period of 60 minutes.

Population-Specific Rules

• Renal Impairment: A 50% dose reduction is required for patients with severe renal impairment (creatinine clearance lt 30 mL/min/1.73 m^2).
• Pediatric Use: Safety and efficacy have not been established for patients under 18 years of age.

Research Evidence / Overview of Studies

This section describes how the drug has been studied in clinical research and summarizes the evidence available from published trials. This information is descriptive of the research and does not offer medical advice or treatment recommendations.

Mechanism of Study

Research has explored the drug's mechanism, which involves targeting two distinct pathways and its association with symptom changes. The combination formulation was studied in trials to assess its bioavailability.

Key Clinical Trial Findings

Phase III Trial Results

A Phase III trial examined the treatment's impact on symptoms. The study included 1,200 participants with the condition. Studies assessed whether the treatment was associated with a reduction in pain and changes in mobility. The primary outcome evaluated was the change in symptom score from baseline to Week 12. The trials also examined outcomes when the full course was taken versus when treatment was discontinued early.

Safety-Related Outcomes

Studies included participants from elderly populations to evaluate safety-related outcomes. The most commonly reported side effects detailed in the trial reports included nausea, headache, and mild fatigue. Research also explored whether the treatment was associated with a change in the risk of long-term complications. The clinical trials explored the drug's use in individuals with mild to moderate conditions.

Key Studies & References Efficacy and Safety of Blastomat in Condition X: A Randomized, Double-Blind, Phase III Trial (BLAST-301)

Common questions about Blastomat (FAQ)

Q: How long does it usually take for Blastomat to start working?

A: According to official regulatory documents, the active ingredient in Blastomat, temozolomide, is rapidly absorbed after oral administration. It typically reaches its peak concentration in the bloodstream in about one hour. This information describes the speed at which the drug enters your system, but it is not the same as the time it takes to see clinical effects related to your treatment.

Q: Can Blastomat affect my ability to drive or operate machinery?

A: Official regulatory documents state that taking this medicine may cause you to feel tired or sleepy. If these effects are experienced, it is described in the safety information that driving or operating machinery may be impacted. For this reason, regulatory labels state that such activities should be avoided until patients know how the medicine affects them.

Q: Is Blastomat known to cause weight gain or loss?

A: Studies and official information indicate that decreased weight is a common side effect reported in clinical trials. This is often associated with anorexia, which is a loss of appetite also noted as a very common side effect. Weight changes are monitored as part of the overall safety profile of the medication.

Q: Can Blastomat affect my mood or mental health?

A: Official product information notes that certain psychiatric effects have been reported in patients using this medicine. These documented adverse reactions can include feelings of depression, anxiety, agitation, and confusion. This information is listed in the adverse reactions section of the regulatory label.

Q: What are the signs of a possible allergic reaction to Blastomat?

A: Serious allergic reactions, though uncommon, have been documented in regulatory labels. Signs may include hives, wheezing, or difficulty breathing. These may be symptoms of a severe reaction known as anaphylaxis. Official information also notes a risk of severe skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis.

Q: How quickly is Blastomat eliminated from the body?

A: According to official regulatory documents, the active substance, temozolomide, is rapidly eliminated from the body. The mean elimination half-life—the time it takes for half the drug to be removed from the bloodstream—is reported to be approximately 1.8 hours. This process of elimination is part of the drug’s pharmacokinetic profile.

Q: Can people with a history of heart problems use Blastomat?

A: Regulatory documents report that uncommon cardiovascular side effects have occurred with the use of this medication. For example, palpitation (a rapid or irregular heartbeat) is listed as an uncommon adverse event. Official information indicates that this medicine reports documented side effects.

Blastomat capsules must be stored in alignment with regulatory mandates to ensure stability and safety. The product requires storage at Controlled Room Temperature, typically 25 C (77 F), and must be protected from excess heat and moisture. The medicine should be kept in its original container, which must be tightly closed at all times.

Due to its classification, the product must be stored out of the sight and reach of children. Capsules must be swallowed whole; if accidentally damaged, rigorous precautions are required to avoid contact with skin or mucous membranes.

Disposal must follow special procedures for cytotoxic waste. Unused or expired capsules must not be thrown away in the household trash or flushed down the toilet. Patients are instructed to return the unused medicine to a pharmacy or healthcare provider for approved environmental handling.